Læknablaðið - 15.12.2000, Blaðsíða 31

FRÆÐIGREINAR / GÁTTATIF
Heimildir
1. Cairns JA, Connolly SJ. Nonrheumatic atrial fibrillation: risk
of stroke and role of antithrombotic therapy. Circulation 1991;
84:469-81.
2. Go AS, Hylek EM, Philips KA, Henault LE, Selby JV, Singer
DE. Prevalence of atrial fibrillation, national implications for
management and stroke prevention: the anticoagulation and
risk factors for atrial fibrillation (ATRIA) study [abstract].
Circulation 1999; 100:1-397.
3. Arnar DO, Danielsen R. Factors predicting maintenance of
sinus rhythm after direct current cardioversion of atrial
fibrillation and flutter. Cardiology 1996; 87:181-8.
4. Murphy MT, Grimm RA, Lauer MS, Klein AL, Lin SS, Chung
MK, et al. Obesity: a powerful correlate of lone atrial
fibrillation independent of blood pressure [abstract].
Circulation 1999; 100,1-824.
5. Brugada R, Tapscott T, Czermuszewics GZ, Manan AJ,
Iglesias A, Mont L, et al. Identification of a genetic locus for
familial atrial fibrillation. N Engl J Med 1997; 336: 905-11.
6. Yamashita T, Murukawa Y, Sezaki K, Inoue M, Hayami M,
Shuzui Y, et al. Circadian variation of paroxysmal atrial
fibrillation. Circulation 1997; 96:1537-41.
7. Coumel P. Autonomic influences in atrial fibrillation. J
Cardiovasc Electrophysiol 1996; 7: 999-1007.
8. Martins JB, Arnar DO. Assessment of the role of the
autonomic nervous system in tachycardias. In: Zipes DP, Jalife
J, eds. Cardiac Electrophysiology: from cell to bedside.
Philadelphia: WB Saunders; 1999:828-34.
9. Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic
effects of an irregular sequence of ventricular cycle lengths
during atrial fibrillation. J Am Coll Cardiol 1997; 30:1039-45.
10. Packer DL, Bardy GH, Worley SJ, Samitu MS, Cobb FR,
Coleman RE, et al. Tachycardia induced cardiomyopathy: a
reversible form of left ventricular dysfunction. Am J Cardiol
1986; 57:563-70.
11. Wolf PA, Dauber TR, Thomas HE Jr, Kannell WB.
Epidemiologic assesment of chronic atrial fibrillation. The
Framingham Study. Neurology 1978; 28: 973-7.
12. Arnar DO, Danielsen R. Gáttatif og blóðþynning.
Læknablaðið 1992; 78:419-22.
13. Atrial fibrillation investigators group. Risk factors for stroke
and efficacy of antithrombotic therapy in atrial fibrillation:
analysis of pooled data from Five randomized controlled trials.
Arch Intern Med 1992; 116: 6-12.
14. Hart RG, Benavente O, McBride R, Pearce LA.
Antithrombotic therapy to prevent stroke in patients with
atrial fibrillation: A meta-analysis. Ann Intern Med 1999; 131:
492-501.
15. Arnar DO, Danielsen R. Frumárangur af rafvendingu vegna
hjartsláttartruflana frá gáttum. Læknablaðið 1992; 78: 87-93.
16. Kerber RE. Transthoracic cardioversion of atrial fibrillation
and flutter: standar techniques and new advances. Am J
Cardiol 1996; 78/Suppl 8A: 22-6.
17. Bjerkelund CJ, Orning OM. The efficacy of anticoagulation in
preventing embolism related to DC electrical cardioversion of
atrial fibrillation. Am J Cardiol 1969; 23: 208-15.
18. Arnold AZ, Mick MJ, Mazurek MP, Loop FD, Trohman RG.
Role of prophylactic anticoagulation for direct current
cardioversion in patients with atrial fibrillation or atrial
flutter. J Am Coll Cardiol 1992; 19: 851-5.
19. Laupacis A, Alberts G, Dalen JE, Dunn MI, Jacobson AK,
Singer DE. Antithrombotic therapy in atrial Fibrillation. Chest
1998; 114/Suppl: 579S-589S.
20. Collins LJ, Silverman DI, Douglas PS, Manning WJ.
Cardioversion of nonrheumatic atrial fibrillation: reduced
thromboembolic complications with 4 weeks of
precardioversion anticoagulation are related to atrial
thrombus resolution. Circulation 1995; 92:156-9.
21. Manning WJ, Silverman DI, Katz SA, Riley MF, Come PC,
Doherty RM, et al. Impaired left atrial mechanical function
after cardioversion: relation to duration of atrial fibrillation. J
Am Coll Cardiol 1994; 23:1535-40.
22. Arnar DO, Danielsen R. Short term heparin versus coumadin
anticoagulation prior to electroconversion of atrial
arrhythmias [abstract]. XIV Nordic Congress of Cardiology,
Aarhus, June 2-4,1993.
23. Weigner MJ, Caulfíeld TA, Danias PG, Silverman DI,
Manning WJ. Risk for clinical thromboembolism associated
with conversion to sinus rhythm in patients with atrial
fibrillation lasting less than 48 hours. Ann Intern Med 1997;
126: 615-20.
24. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green
M, et al. Amiodarone to prevent recurrence of atrial
fíbrillation. N Engl J Med 2000; 342:913-20.
25. Stambler BS, Wood MA, Ellenbogen KA, Perry KT,
Wakefield LK, VanderLugt JT, et al. Efficacy and safety of
repeated intravenous doses of ibutilide for conversion of atrial
flutter or fibrillation. Circulation 1996; 94:1613-21.
26. Torp-Pedersen C, Möller M, Bloch-Thomsen PE, Kober L,
Sandoe E, Egstrup K, et al. Dofetilide in patients with
congestive heart failure and left ventricular dysfunction. N
Engl J Med 1999; 341: 857-65.
27. Prystowsky EW. Proarrhythmia during drug tratment of
supraventricular taschycardia: paradoxical risk of sinus
rhythm for sudden death. Am J Cardiol 1996; 78: 35-41.
28. Velebit V, Podrid P, Lown B, Cohen BH, Graboys TB.
Aggrevation and provocation of ventricular arrhythmias by
antiarrhythmic drugs. Circulation 1982; 65:886-94.
29. Manning WJ, Silverman DI, Gordon SPF, Krumholz HM,
Douglas P. Cardioversion from atrial fibrillation without
prolonged anticoagulation with use of transesophageal
echocardiography to exclude the presence of atrial thrombi. N
Engl J Med 1993; 328: 750-5.
30. Black IW, Fatken D, Sagar KB, Khandheria BK, Leung DY,
Galloway JM, et al. Exclusion of atrial thrombus by
transesophageal echocardiography does not preclude
embolism after cardioversion of atrial fibrillation. Circulation
1994; 89: 2509-13.
31. Klein AL, Grimm RA, Black IW , Leung DY, Chung MK,
Vaughn S, et al. Cardioversion guided by transesophageal
echocardiography. The ACUTE pilot study. Ann Intern Med
1997; 126: 200-9.
32. Oral H, Souza JJ, Michaud GF, Knight B, Goyal R,
Strickberger A, et al. Facilitating transthoracic cardioversion
of atrial fíbrillation with ibutilide pretreatment. N Engl J Med
1999; 340:1849-54.
33. De Bruyn VH, Park TH, Botteron GW, Faddis MN, Baker
BM, Guerrero PA, et al. Pressure assisted cardioversion for
atrial fibrillation [abstract]. Circulation 1998; 98:1-102.
34. Levy S, Ricard P, Guenuoun M, Yapo F, Trigano J, Mansouri C,
et al. Low energy cardioversion of spontaneous atrial
fibrillation. Immediate and long term results. Circulation 1997;
96:253-9.
35. Mittal S, Ayati S, Stein KM, Markowitz SM, Slotwiner SJ,
Scheiner MA, et al. Effect of transthoracic impedance on
cardioversion efficacy: Rectilinear biphasic versus sine wave
monophasic shocks for transthoracic cardioversion of atrial
fíbrillation [abstract]. Circulation 1999,100:1-721.
36. Wellens HJJ, Lau C-P, Luederitz B, Akhtar M, Waldo A,
Camm AJ, et al. Atrioverter: an implantable device for the
treatment of atrial fibrillation. Circulation 1998; 98:1651-6.
37. Sutton R, Kenny RA. The natural history of sick sinus
syndrome. PACE 1986; 9:1110-4.
38. Saksena S, Prakash A, Hill M, Krol RB, Munsit AN, Matthew
PP. Prevention of recurrent atrial fibrillation with chronic dual
site atrial pacing. J Am Coll Cardiol 1996; 28: 687-94.
39. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M,
Quiniou G, et al. Spontaneous initiation of atrial fibrillation by
ectopic beats originating in the pulmonary veins. N Engl J Med
1998; 339: 659-66.
40. Cox JC, Boineau JP, Schussler RB, Kater KM, Lappas DG.
Five year experience with the maze procedure for atrial
fibrillation. Ann Thor Surg 1993; 56: 814-23.
41. Haissaguerre M, Jais P Shah DC, Clementy J. Catheter
ablation for atrial fibrillation: clinical electrophysiolgy of
linear lesions. In: Zipes DP, Jalife J, eds. Cardiac
Electrophysiology: from cell to bedside. Philadelphia: WB
Saunders; 1999: 994-1008.
Læknablaðið 2000/86 847